Emergence of serogroup X meningococcal disease in Africa: Need for a vaccine. Xie, O., Pollard, A. J., Mueller, J. E., & Norheim, G. Vaccine, 31(27):2852–2861, June, 2013. ![Emergence of serogroup X meningococcal disease in Africa: Need for a vaccine [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex Neisseria meningitidis is responsible for the seasonal burden and recurrent epidemics of meningitis in an area of sub-Saharan Africa known as the meningitis belt. Historically, the majority of the cases in the meningitis belt are caused by serogroup A meningococci. Serogroup C meningococci were responsible for outbreaks in the meningitis belt in the 1980s, while serogroup W (formerly W-135) has emerged as a cause of epidemic meningitis since 2000. Serogroup X meningococci have previously been considered a rare cause of sporadic meningitis, but during 2006–2010, outbreaks of serogroup X meningitis occurred in Niger, Uganda, Kenya,Togo and Burkina Faso, the latter with at least 1300 cases of serogroup X meningitis among the 6732 reported annual cases. While serogroup X has not yet caused an epidemic wave of the scale of serogroup A in 1996–1997 or serogroup W in Burkina Faso during 2002, the existing reports suggest a similar seasonal hyperendemicity and capacity for localised epidemics. Serogroup X incidence appears to follow a pattern of highly localised clonal waves, and in affected districts, other meningococcal serogroups are usually absent from disease. Currently, no licensed vaccine is available against serogroup X meningococci. Following the introduction of a monovalent serogroup A conjugate vaccine (MenAfriVac®) in the meningitis belt and the upcoming introduction of pneumococcal conjugate vaccines, vaccine-based prevention of serogroup X may become a public health need. The serogroup X polysaccharide capsule is the most likely target for vaccine development, but recent data also indicate a potential role for protein-based vaccines. A multivalent vaccine, preferably formulated as a conjugate vaccine and covering at least serogroups A, W, and X is needed, and the efforts for vaccine development should be intensified.
@article{xie_emergence_2013,
title = {Emergence of serogroup {X} meningococcal disease in {Africa}: {Need} for a vaccine},
volume = {31},
issn = {0264-410X},
shorttitle = {Emergence of serogroup {X} meningococcal disease in {Africa}},
url = {http://www.sciencedirect.com/science/article/pii/S0264410X13004751},
doi = {10.1016/j.vaccine.2013.04.036},
abstract = {Neisseria meningitidis is responsible for the seasonal burden and recurrent epidemics of meningitis in an area of sub-Saharan Africa known as the meningitis belt. Historically, the majority of the cases in the meningitis belt are caused by serogroup A meningococci. Serogroup C meningococci were responsible for outbreaks in the meningitis belt in the 1980s, while serogroup W (formerly W-135) has emerged as a cause of epidemic meningitis since 2000. Serogroup X meningococci have previously been considered a rare cause of sporadic meningitis, but during 2006–2010, outbreaks of serogroup X meningitis occurred in Niger, Uganda, Kenya,Togo and Burkina Faso, the latter with at least 1300 cases of serogroup X meningitis among the 6732 reported annual cases. While serogroup X has not yet caused an epidemic wave of the scale of serogroup A in 1996–1997 or serogroup W in Burkina Faso during 2002, the existing reports suggest a similar seasonal hyperendemicity and capacity for localised epidemics. Serogroup X incidence appears to follow a pattern of highly localised clonal waves, and in affected districts, other meningococcal serogroups are usually absent from disease. Currently, no licensed vaccine is available against serogroup X meningococci. Following the introduction of a monovalent serogroup A conjugate vaccine (MenAfriVac®) in the meningitis belt and the upcoming introduction of pneumococcal conjugate vaccines, vaccine-based prevention of serogroup X may become a public health need. The serogroup X polysaccharide capsule is the most likely target for vaccine development, but recent data also indicate a potential role for protein-based vaccines. A multivalent vaccine, preferably formulated as a conjugate vaccine and covering at least serogroups A, W, and X is needed, and the efforts for vaccine development should be intensified.},
number = {27},
urldate = {2014-08-10},
journal = {Vaccine},
author = {Xie, Ouli and Pollard, Andrew J. and Mueller, Judith E. and Norheim, Gunnstein},
month = jun,
year = {2013},
pages = {2852--2861},
}
Downloads: 0
{"_id":"WDhqL8y77mied3Sz6","bibbaseid":"xie-pollard-mueller-norheim-emergenceofserogroupxmeningococcaldiseaseinafricaneedforavaccine-2013","author_short":["Xie, O.","Pollard, A. J.","Mueller, J. E.","Norheim, G."],"bibdata":{"bibtype":"article","type":"article","title":"Emergence of serogroup X meningococcal disease in Africa: Need for a vaccine","volume":"31","issn":"0264-410X","shorttitle":"Emergence of serogroup X meningococcal disease in Africa","url":"http://www.sciencedirect.com/science/article/pii/S0264410X13004751","doi":"10.1016/j.vaccine.2013.04.036","abstract":"Neisseria meningitidis is responsible for the seasonal burden and recurrent epidemics of meningitis in an area of sub-Saharan Africa known as the meningitis belt. Historically, the majority of the cases in the meningitis belt are caused by serogroup A meningococci. Serogroup C meningococci were responsible for outbreaks in the meningitis belt in the 1980s, while serogroup W (formerly W-135) has emerged as a cause of epidemic meningitis since 2000. Serogroup X meningococci have previously been considered a rare cause of sporadic meningitis, but during 2006–2010, outbreaks of serogroup X meningitis occurred in Niger, Uganda, Kenya,Togo and Burkina Faso, the latter with at least 1300 cases of serogroup X meningitis among the 6732 reported annual cases. While serogroup X has not yet caused an epidemic wave of the scale of serogroup A in 1996–1997 or serogroup W in Burkina Faso during 2002, the existing reports suggest a similar seasonal hyperendemicity and capacity for localised epidemics. Serogroup X incidence appears to follow a pattern of highly localised clonal waves, and in affected districts, other meningococcal serogroups are usually absent from disease. Currently, no licensed vaccine is available against serogroup X meningococci. Following the introduction of a monovalent serogroup A conjugate vaccine (MenAfriVac®) in the meningitis belt and the upcoming introduction of pneumococcal conjugate vaccines, vaccine-based prevention of serogroup X may become a public health need. The serogroup X polysaccharide capsule is the most likely target for vaccine development, but recent data also indicate a potential role for protein-based vaccines. A multivalent vaccine, preferably formulated as a conjugate vaccine and covering at least serogroups A, W, and X is needed, and the efforts for vaccine development should be intensified.","number":"27","urldate":"2014-08-10","journal":"Vaccine","author":[{"propositions":[],"lastnames":["Xie"],"firstnames":["Ouli"],"suffixes":[]},{"propositions":[],"lastnames":["Pollard"],"firstnames":["Andrew","J."],"suffixes":[]},{"propositions":[],"lastnames":["Mueller"],"firstnames":["Judith","E."],"suffixes":[]},{"propositions":[],"lastnames":["Norheim"],"firstnames":["Gunnstein"],"suffixes":[]}],"month":"June","year":"2013","pages":"2852–2861","bibtex":"@article{xie_emergence_2013,\n\ttitle = {Emergence of serogroup {X} meningococcal disease in {Africa}: {Need} for a vaccine},\n\tvolume = {31},\n\tissn = {0264-410X},\n\tshorttitle = {Emergence of serogroup {X} meningococcal disease in {Africa}},\n\turl = {http://www.sciencedirect.com/science/article/pii/S0264410X13004751},\n\tdoi = {10.1016/j.vaccine.2013.04.036},\n\tabstract = {Neisseria meningitidis is responsible for the seasonal burden and recurrent epidemics of meningitis in an area of sub-Saharan Africa known as the meningitis belt. Historically, the majority of the cases in the meningitis belt are caused by serogroup A meningococci. Serogroup C meningococci were responsible for outbreaks in the meningitis belt in the 1980s, while serogroup W (formerly W-135) has emerged as a cause of epidemic meningitis since 2000. Serogroup X meningococci have previously been considered a rare cause of sporadic meningitis, but during 2006–2010, outbreaks of serogroup X meningitis occurred in Niger, Uganda, Kenya,Togo and Burkina Faso, the latter with at least 1300 cases of serogroup X meningitis among the 6732 reported annual cases. While serogroup X has not yet caused an epidemic wave of the scale of serogroup A in 1996–1997 or serogroup W in Burkina Faso during 2002, the existing reports suggest a similar seasonal hyperendemicity and capacity for localised epidemics. Serogroup X incidence appears to follow a pattern of highly localised clonal waves, and in affected districts, other meningococcal serogroups are usually absent from disease. Currently, no licensed vaccine is available against serogroup X meningococci. Following the introduction of a monovalent serogroup A conjugate vaccine (MenAfriVac®) in the meningitis belt and the upcoming introduction of pneumococcal conjugate vaccines, vaccine-based prevention of serogroup X may become a public health need. The serogroup X polysaccharide capsule is the most likely target for vaccine development, but recent data also indicate a potential role for protein-based vaccines. A multivalent vaccine, preferably formulated as a conjugate vaccine and covering at least serogroups A, W, and X is needed, and the efforts for vaccine development should be intensified.},\n\tnumber = {27},\n\turldate = {2014-08-10},\n\tjournal = {Vaccine},\n\tauthor = {Xie, Ouli and Pollard, Andrew J. and Mueller, Judith E. and Norheim, Gunnstein},\n\tmonth = jun,\n\tyear = {2013},\n\tpages = {2852--2861},\n}\n\n","author_short":["Xie, O.","Pollard, A. J.","Mueller, J. E.","Norheim, G."],"key":"xie_emergence_2013","id":"xie_emergence_2013","bibbaseid":"xie-pollard-mueller-norheim-emergenceofserogroupxmeningococcaldiseaseinafricaneedforavaccine-2013","role":"author","urls":{"Paper":"http://www.sciencedirect.com/science/article/pii/S0264410X13004751"},"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/robin.marlow","dataSources":["ix72eqAAMGCuupBaz"],"keywords":[],"search_terms":["emergence","serogroup","meningococcal","disease","africa","need","vaccine","xie","pollard","mueller","norheim"],"title":"Emergence of serogroup X meningococcal disease in Africa: Need for a vaccine","year":2013}